Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Abstract Alzheimer’s disease (AD) is characterized by progressive cognitive decline, severe brain atrophy and neuroinflammation. We conducted a randomized, double-blind, placebo-controlled, parallel-group phase 2a clinical trial that tested the safety and efficacy of laromestrocel, a bone-marrow-der...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Brian G. Rash, Kevin Ramdas, Nataliya Agafonova, Eric Naioti, Lisa McClain‐Moss, Zarin Zainul, Brittany Varnado, Kevin Peterson, Michael Brown, Thiago Peixoto Leal, Steven Kopcho, Raul Carballosa, Paayal Patel, Mark Brody, Brad Herskowitz, Ana Fuquay, Savannah Rodriguez, Alan F. Jacobson, Ramón Fernández de León, Michael A. Pfeffer, Julie Schwartzbard, Jeffrey Botbyl, Anthony A. Oliva, Joshua M. Hare
Materialtyp: Artigo
Språk:engelska
Publicerad: 2025
Länkar:https://doi.org/10.1038/s41591-025-03559-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Internet

https://doi.org/10.1038/s41591-025-03559-0

Liknande verk